GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Insider Ownership

Avacta Group (LSE:AVCT) Insider Ownership : 62.19 % (As of Jun. 05, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avacta Group's insider ownership is 62.19%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avacta Group's Institutional Ownership is 4.74%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avacta Group's Float Percentage Of Total Shares Outstanding is 0.00%.


Avacta Group Insider Ownership Historical Data

The historical data trend for Avacta Group's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Insider Ownership Chart

Avacta Group Historical Data

The historical data trend for Avacta Group can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Insider Ownership 79.67 79.46 78.47 78.47 78.47 77.19 77.21 63.53 62.19 62.19

Avacta Group Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Avacta Group (LSE:AVCT) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines